EA202190653A1 - Конъюгаты связывающего белка с токсином, содержащие антрациклины, и их применение в иммуноонкологических целях - Google Patents

Конъюгаты связывающего белка с токсином, содержащие антрациклины, и их применение в иммуноонкологических целях

Info

Publication number
EA202190653A1
EA202190653A1 EA202190653A EA202190653A EA202190653A1 EA 202190653 A1 EA202190653 A1 EA 202190653A1 EA 202190653 A EA202190653 A EA 202190653A EA 202190653 A EA202190653 A EA 202190653A EA 202190653 A1 EA202190653 A1 EA 202190653A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immuno
conjugates
binding protein
toxin containing
oncological
Prior art date
Application number
EA202190653A
Other languages
English (en)
Russian (ru)
Inventor
Ульф Гравундер
Роджер Берли
Лоренц Вальдмайер
Франческа Претто
Original Assignee
ЭнБиИ - ТЕРАПЬЮТИКС АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭнБиИ - ТЕРАПЬЮТИКС АГ filed Critical ЭнБиИ - ТЕРАПЬЮТИКС АГ
Publication of EA202190653A1 publication Critical patent/EA202190653A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EA202190653A 2018-10-11 2019-10-11 Конъюгаты связывающего белка с токсином, содержащие антрациклины, и их применение в иммуноонкологических целях EA202190653A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18199879.0A EP3636284A1 (en) 2018-10-11 2018-10-11 Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
PCT/EP2019/077644 WO2020074724A1 (en) 2018-10-11 2019-10-11 Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications

Publications (1)

Publication Number Publication Date
EA202190653A1 true EA202190653A1 (ru) 2021-05-26

Family

ID=63833918

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190653A EA202190653A1 (ru) 2018-10-11 2019-10-11 Конъюгаты связывающего белка с токсином, содержащие антрациклины, и их применение в иммуноонкологических целях

Country Status (12)

Country Link
US (1) US20210379194A1 (cg-RX-API-DMAC7.html)
EP (2) EP3636284A1 (cg-RX-API-DMAC7.html)
JP (1) JP7607556B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210075085A (cg-RX-API-DMAC7.html)
CN (1) CN112805037A (cg-RX-API-DMAC7.html)
AU (1) AU2019358518A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021006269A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112848A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190653A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021003136A (cg-RX-API-DMAC7.html)
PH (1) PH12021550750A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020074724A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ror1結合タンパク質を発現する細胞を培養する方法
WO2023217227A1 (zh) 2022-05-12 2023-11-16 先声再明医药有限公司 喜树碱类衍生物及配体-药物偶联物
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
BR122020025870B1 (pt) 2014-12-23 2024-01-09 Nbe-Therapeutics Ag Método para a produção de um conjugado de proteína de ligaçãofármaco
US20180028682A1 (en) 2015-02-09 2018-02-01 Nbe Therapeutics Ag Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
CA3001941A1 (en) 2015-10-30 2017-05-04 Nbe-Therapeutics Ag Anti-ror1 antibodies
US20190112385A1 (en) 2015-10-30 2019-04-18 Nbe-Therapeutics Ag Anti-mesothelin antibodies
MX2018008926A (es) * 2016-01-20 2019-01-10 Scripps Research Inst Composiciones de anticuerpo contra ror1 y métodos relacionados.
CN109311982A (zh) * 2016-01-20 2019-02-05 斯克利普斯研究所 Ror2抗体组合物和相关方法
PL3964529T3 (pl) * 2016-01-22 2025-10-27 MabQuest SA Nieblokujące przeciwciała specyficzne względem pd1
SG11201901624RA (en) * 2016-09-07 2019-03-28 Univ Canberra Lysine specific histone demethylase-1 inhibitors and uses therefor
WO2018103739A1 (zh) * 2016-12-09 2018-06-14 凯惠科技发展(上海)有限公司 抗体药物偶联物、制备方法、中间体、药物组合物及应用
JP7359700B2 (ja) * 2017-06-20 2023-10-11 ソレント・セラピューティクス・インコーポレイテッド Cd38抗体薬物コンジュゲート
US20210139579A1 (en) * 2017-07-20 2021-05-13 Nbe-Therapeutics Ag Multispecific antibody product that binds to different ror1 epitopes
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
KR20230008269A (ko) * 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules

Also Published As

Publication number Publication date
WO2020074724A1 (en) 2020-04-16
CN112805037A (zh) 2021-05-14
EP3636284A1 (en) 2020-04-15
PH12021550750A1 (en) 2022-02-21
BR112021006269A2 (pt) 2021-08-10
JP7607556B2 (ja) 2024-12-27
JP2022512672A (ja) 2022-02-07
CA3112848A1 (en) 2020-04-16
KR20210075085A (ko) 2021-06-22
AU2019358518A1 (en) 2021-04-08
US20210379194A1 (en) 2021-12-09
MX2021003136A (es) 2021-08-19
EP3863681A1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
CO2018005436A2 (es) Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica
MX2020000960A (es) Anticuerpos anti-tigit.
PH12020551716A1 (en) Anti-ror antibody constructs
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
JOP20200343A1 (ar) بروتين ربط مولد ضد مضاد لـ steap1
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
PH12021551425A1 (en) Bifunctional anti-pd-1/sirpa molecule
EA202091350A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
AR120883A1 (es) Anticuerpos anti-fgfr2b
EA201992281A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos
BR112016024525A2 (pt) novos anticorpos anti-rnf43 e métodos de uso
MX2025009320A (es) Anticuerpos anti-cd19 novedosos
MX2022007961A (es) Nuevos anticuerpos anti-fgfr2b.
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
PH12021550750A1 (en) Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
BR112021011729A2 (pt) Tubulisinas e conjugados de proteína-tubulisina
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2022007960A (es) Nuevos anticuerpos anti-fgfr2b.
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof